Preventing heart damage from cancer treatment with a specific protein activation
Prevention of anthracycline-induced cardiotoxicity by Nur77 activation
This study is looking at how a protein called Nur77 might help protect the heart from damage caused by the chemotherapy drug doxorubicin, which is often used to treat cancer, to see if boosting Nur77 can help prevent heart problems for patients receiving this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10857156 on NIH RePORTER |
What this research studies
This research investigates how activating a protein called Nur77 can protect the heart from damage caused by the chemotherapy drug doxorubicin, which is commonly used to treat various cancers. The study aims to understand the mechanisms behind heart toxicity associated with this drug and whether enhancing Nur77 expression can prevent heart-related side effects in patients undergoing treatment. By exploring the relationship between Nur77 and heart health, the research seeks to develop a potential therapeutic strategy to mitigate the harmful effects of doxorubicin on cardiac function.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult cancer patients who are receiving doxorubicin as part of their treatment regimen.
Not a fit: Patients who are not undergoing treatment with doxorubicin or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect cancer patients from heart damage caused by chemotherapy.
How similar studies have performed: Previous research has shown promising results in using similar approaches to protect against chemotherapy-induced cardiotoxicity, indicating potential for success in this area.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Sun, Jianxin — Thomas Jefferson University
- Study coordinator: Sun, Jianxin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.